ISSN 2472-0429

Advances in Cancer Prevention
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Review Article   
  • Adv Cancer Prev 2: 122,
  • DOI: 10.4172/2472-0429.1000122

Evaluation of Docetaxel vs. Tamoxifen in Combined Therapies Based on Overall Survival Rate (OSR) Endpoint among Female Breast Cancer Patients

Oluwafemi Olawuyi* and Melanie Tidman
College of Graduate Health Studies, A.T. Still University, , MO, USA
*Corresponding Author : Oluwafemi Olawuyi, College of Graduate Health Studies, A.T. Still University, MO, USA, Tel: +1-866-626-2878, Email: femibiotec@gmail.com

Received Date: Feb 10, 2017 / Accepted Date: Feb 25, 2017 / Published Date: Feb 28, 2017

Abstract

In this review, overall survival rate (OSR) result and safety data were evaluated based on data from four clinical trials on combined therapies of Docetaxel and Tamoxifen among breast cancer patients, which were published in peer-reviewed journals. Data was extracted from single treatment trials of Docetaxel plus Cisplatin, and Tamoxifen plus Vorinostat, and randomized trials of Docetaxel plus Capecitabine, and Tamoxifen plus Buserelin. Docetaxel was found to have slightly longer OSR than Tamoxifen in combined therapies, and it has better individual strength in combined therapies based on OSR comparison in the trials’ treatment arms. However, a considerable number of toxicities caused by combined therapies of both drugs negates the superiority of the efficacy of combined therapies of one of the drugs over the other. Although other combined cancer drugs boost efficacy of Docetaxel and Tamoxifen in the combined therapies, they should be selected to minimize the toxicities in combined therapies of both drugs.

Keywords: Docetaxel; Tamoxifen; Overall survival rate; OSR; Breast cancer

Citation: Olawuyi O, Tidman M (2017) Evaluation of Docetaxel vs. Tamoxifen in Combined Therapies Based on Overall Survival Rate (OSR) Endpoint among Female Breast Cancer Patients. Adv Cancer Prev 2: 122. Doi: 10.4172/2472-0429.1000122

Copyright: © 2017 Olawuyi O, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Post Your Comment Citation
Share This Article
Recommended Conferences
Article Usage
  • Total views: 4887
  • [From(publication date): 0-2017 - Dec 05, 2024]
  • Breakdown by view type
  • HTML page views: 4231
  • PDF downloads: 656
Top